It is always a good sign when your presentation is interrupted by a standing ovation. This was the fate of Tom Powles, director of Barts Cancer Centre in London, at an ESMO presidential symposium where he gave the detailed results of the Phase III EV-302/KEYNOTE-A39 trial looking at the combination of Seagen Inc. and Astellas Pharma, Inc.'s antibody-drug conjugate Padcev (enfortumab vedotin) and Merck & Co., Inc.'s checkpoint inhibitor Keytruda (pembrolizumab), as front-line therapy in patients with locally advanced or metastatic urothelial carcinoma (UC), which covers almost all bladder cancers.
The combo was the first regimen containing an ADC and an anti-PD-1/L1 agent to gain a US green light in...
Welcome to In Vivo
Create an account to read this article
Already a subscriber?